The requirement for a certain degree of expression to enable cancer targeting by specific drugs is not at odds; thus, for example, patients are eligible for anti-HER2 antibody therapies if their HER2-positive breast cancer reach a certain predefined immunohistochemical score. The gene discussed is ERBB2; the disease is breast cancer.